Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Renal Cancer Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

10 recruiting trials for Renal Cancer. Eligibility criteria explained in plain English.

TrialFinderData lists 10 Renal Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 is the largest group at 67% (2 studies); the largest phase groups are Phase 1: 2, Phase 2: 1.

Research is led by Hospices Civils de Lyon (1), Institut Claudius Regaud (1), Dana-Farber Cancer Institute (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is GaGnostic (diagnostic_test, 3 trials), followed by Blood draws, For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Track Renal Cancer trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT03787056

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric...

Sponsor: Hospices Civils de LyonEnrolling: 41017 locations
RECRUITINGNCT06967961

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible...

Sponsor: Institut Claudius RegaudEnrolling: 4501 location
RECRUITINGNCT04115254

Stereotactic Magnetic Resonance Guided Radiation Therapy

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 3972 locations
RECRUITINGNCT05326620

National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)

PRO-RCC is a nationwide long-term cohort for the collection of real-world clinical data, patient reported outcome measures (PROMs) and patient reported experience measures (PREMs)...

Sponsor: PROspective Renal Cancer Cohort FoundationEnrolling: 200020 locations
RECRUITINGPhase 1NCT06595329

Comparison Between Epidural Analgesia and Intrathecal Opioid Analgesia for Pain Management in Open Nephrectomy

Nephrectomy is a surgical procedure of choice for patients suffering from renal cell carcinoma (RCC). Even though the laparoscopic approach is considered to cause fewer...

Sponsor: University Hospital of SplitEnrolling: 401 location
RECRUITINGNCT00026884

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the...

Sponsor: National Cancer Institute (NCI)Enrolling: 59501 location
RECRUITINGNCT05060783

Renal Cancer Detection With Liquid Biopsy

Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free...

Sponsor: Zealand University HospitalEnrolling: 2001 location
RECRUITINGPhase 2NCT03175224

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET...

Sponsor: Apollomics Inc.Enrolling: 49720 locations
RECRUITINGNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer...

Sponsor: Adela, IncEnrolling: 700017 locations
RECRUITINGPhase 1NCT05873686

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid...

Sponsor: Nuvectis Pharma, Inc.Enrolling: 14012 locations

Frequently Asked Questions

There are currently 10 clinical trials for Renal Cancer, with 10 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Renal Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Renal Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.